ArticleBMC ophthalmology2025
A preliminary proteomic analysis of tear fluid in patients with high myopia.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement and local ocular inflammatory response: Chronic immune factors in myopia.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundUsing liquid chromatography-tandem mass spectrometry (LC-MS/MS) as a protein quantification technique for the analysis of the proteomic profile of myopia patient tear fluid, to clarify the role of dysregulated proteins in high myopia (HM) in order to provide a more thorough understanding of the molecular processes involved in the development of the disease.
methodsSchirmer strips were used to acquire the tear films from 20 subjects (10 high myopia patients and 10 control subjects). LC-MS/MS was utilized to identify the proteome profile of the tears in order to assess protein interrelationships utilizing bioinformatics.
resultsThe tear preparations from the HM group and the control group included a total of 1544 proteins. The expression of 79 proteins out of the identified ones differed significantly between the two groups. 51 proteins showed overexpression and 28 proteins showed downregulation. 15 differentially expressed proteins (DEPs) were enriched in metabolic pathways, 15 DEPs were enriched in extracellular exomes, and 5 DEPs were enriched in the complement and coagulation cascades pathway. Potentially important proteins and therapeutic targets in human HM include TTR and Antithrombin-III.
conclusionThe proteomic analysis of tear fluid in high myopia patients identifies key proteins and pathways involved in the disease, offering potential biomarkers for its pathogenesis and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.